CFDE Data Portal | Search MIR616

	Label	Description
	MIR616 associations Collection (Entity type)	Associations for MIR616_associations
	MIR616 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	MIR616 Gene (Entity type)	ENSG00000208028 - microRNA 616
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 8 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE206931 WDR5 inhibition WIN 3 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119424 GSE120214 TBXT brachyury inhibition 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE244730 erlotinib PC-9 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 8 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

MIR616 associations

Associations for MIR616_associations

MIR616 associations.tsv

A file from IDG as part of the Harmonizome project

MIR616

ENSG00000208028 - microRNA 616

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 8 v 5 human dn

A Gene Set from LINCS

GSE206931 WDR5 inhibition WIN 3 v 6 human up

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human up

A Gene Set from LINCS

GSE119424 GSE120214 TBXT brachyury inhibition 1 v 3 human up

A Gene Set from LINCS

GSE244730 erlotinib PC-9 0 v 1 human dn

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 8 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.